(Update) Acalabrutinib in CLL and MCL
Acalabrutinib
Zanubrutinib
Obinutuzumab
JADPRO Roundtable Series: Best Practices in the Use of BTK Inhibitors in CLL
NCCN Guidelines for Patients
Cancer.gov
Leukemia & Lymphoma Society